Antimicrobial Activity of *Piper gaudichaudianum* Kuntze and Its Synergism with Different Antibiotics

Mariele Caroline Marques Nogueira Puhl 1, Diógenes Aparício Garcia Cortez 2, Tânia Ueda-Nakamura 3, Celso Vataru Nakamura 3 and Benedito Prado Dias Filho 3,*

1 Programa de Pós-graduação em Ciências Farmacêuticas, Universidade Estadual de Maringá, PR CEP 87020-900, Brazil; E-Mail: marielecaroline@hotmail.com (M.C.M.N.P.)

2 Departamento de Farmácia e Farmacologia, Universidade Estadual de Maringá, PR. CEP 87020-900, Brazil; E-Mail: dagcortez@uem.br (D.A.G.C.)

3 Departamento de Ciências Básicas da Saúde, Universidade Estadual de Maringá, PR. CEP 87020-900 Brazil; E-Mails: tunakamura@uem.br (T.U.N.); cvnakamura@uem.br (C.V.N.)

* Author to whom correspondence should be addressed; E-Mail: bpdfilho@uem.br; Tel.: +55-44-3261-4136; Fax: +55-44-4009-4170.

Received: 22 September 2011; in revised form: 6 November 2011 / Accepted: 14 November 2011 / Published: 1 December 2011

**Abstract:** One of the oldest forms of medical practice is the use of plants for the treatment and prevention of diseases that affect humans. We have studied the antimicrobial activity and synergism of *Piper gaudichaudianum* Kuntze with different antibiotics. The crude extract from the leaves of *P. gaudichaudianum* was submitted to chromatographic separation, resulting in five fractions. Fraction F3 contained a chromone (2,2-dimethyl-6-carboxycroman-4-one), and fraction F2 contained isomers that are prenylated derivatives of benzoic acid [4-hydroxy-(3',7'-dimethyl-1'-oxo-octa-E-2'-6'-dienyl)benzoic acid and 4-hydroxy-(3',7'-dimethyl-1'-oxo-octa-Z-6'-dienyl) benzoic acid]. The chemical structures of both compounds were determined by analysis of $^1$H-NMR, $^{13}$C-NMR, COZY, DEPT, HMQC, and HMBC spectral data, and by comparison with data in the literature. The crude extract, fraction F2, and fraction F3 showed good activity against *Staphylococcus aureus*, *Bacillus subtilis*, and *Candida tropicalis*. The two benzoic acid derivatives only showed activity against *S. aureus* and *B. subtilis*. The bioautographic analysis showed an inhibition zone only in fraction F2. Fractions F2 and F3 showed synergism in combination with ceftriaxone, tetracycline, and vancomycin. Morphological
changes in form and structure were found by scanning electron microscopy in *S. aureus* treated with the combination of fraction F2 with vancomycin.

**Keywords:** *Piper gaudichaudianum*; chromone; prenylated derivatives; antimicrobial activity; synergism

---

1. **Introduction**

Active ingredients derived from natural products are of great importance for the discovery of new centers, which serve as a model in semi-synthesis and total syntheses [1]. Of the drugs currently used worldwide, about one-third are derived from natural products or are semi-synthetic [2]. The family Piperaceae is predominantly tropical, and includes 5 to 8 genera and approximately 2,000 species. The family is represented in Brazil by about 500 species, occurring in forest areas, particularly in the Atlantic Forest [3]. Chemical studies on *Piper* species have resulted in the isolation of many biologically active natural products, such as pyrenes, lignans, neolignans, terpenes, propenylphenols, chalcones, flavones, benzopyrenes, chromenes, lactones, and amides [4,5].

Teixeira [6] carried out a phytochemical study of immature and mature fruits of *P. gaudichaudianum*, and isolated and identified five non-volatile components: 5,7-Dihydroxy flavanone, (pinocembrine, 1), 2,2-dimethyl-6-carboxycroman-4-one methyl ester (2), 2-(2'-hydroxy-5'-methoxyphenyl)-N-(2''-methylpropenyl)-2-oxo-acetamide (3), (E)-4(3'-decenyl) phenol (gibbilimbol B, 4), and 2,2-dimethyl-2H-1 benzopyran-6-carboxylate (5). Substances 2 and 3 showed inhibitory activity against the microorganisms *Enterococcus faecium*, *Micrococcus luteus*, and *Staphylococcus faecium*, and substance 4 showed activity against *Rhodococcus equi*.

Ethanol extracts of the stem and leaves of *P. gaudichaudianum* and *P. aduncum* have been evaluated for trypanocidal activity against the epimastigote form of the Y strain of *Trypanosoma cruzi*, revealing a pronounced effect (IC₅₀ = 404 and 112.4 µg/mL, respectively). Both compounds are chromenes, and the prenylated forms were more powerful. The activity of compounds 1 and 2 was modified through hydrogenation reactions and esterification, which showed that the reverse acid is important for the activity of this class of substances, as well as the unsaturation of the benzopyrene subunit [7].

*S. aureus* is one of the most important pathogenic bacteria, causing a wide range of infections from local and usually superficial infections to extremely severe systemic ones [8]. *S. aureus* can also cause toxic infections [9]. Methicillin-resistant *S. aureus* (MRSA) is resistant to all beta-lactam antibiotics. Resistant pathogenic strains have been the main cause of nosocomial infections, causing considerable mortality of patients, and high health-care costs [10-12].

Antimicrobial combinations are employed in order to prevent the emergence of resistant strains or to increase activity, in cases of mixed infections or to reduce the toxicity of a substance without compromising the antimicrobial action. Interactions between different drugs may be synergistic, antagonistic, or indifferent.

Many studies have examined the synergism involving the action of plant derivatives against *S. aureus*. The porphyrin pheophorbide A and flavonolignan 5'-methoxyhydnocarpin (5'-MHC),
isolated from plants of the genus *Berberis*, inhibit the efflux pump in *S. aureus*, thereby boosting the antibacterial alkaloid berberine [13]. Piperine, the alkaloid found in plants of the family Piperaceae, has synergistic activity in combination with ciprofloxacin against *S. aureus*, including MRSA strains [14]. Totarol, also a phenolic diterpene, showed activity in inhibiting the efflux pump of *S. aureus* [15]. The purpose of this study was to isolate the chemicals present in the leaves of *P. gaudichaudianum*, and to evaluate their antibacterial activity and synergism with other antibiotics against *S. aureus*.

2. Results and Discussion

The crude extract from the leaves of *P. gaudichaudianum* was fractionated, resulting in five fractions. Fraction F3 contained a chromone (2,2-dimethyl-6-carboxycroman-4-one) (Figure 1). Fraction F2 contained isomers that are prenylated derivatives of benzoic acid (4-hydroxy-(3',7'-dimethyl-1'-oxo-octa-2'-6'-dienyl) benzoic acid and 4-hydroxy-(3',7'-dimethyl-1'-oxo-octa-2'-Z-6'-dienyl) benzoic acid) (Figure 2). The chemical structures of both compounds were determined by analysis of $^1$H-NMR, $^{13}$C-NMR, COZY, DEPT, HMQC, and HMBC spectral data, and by comparison with values reported in the literature [6,16].

![Figure 1. 2,2-dimethyl-6-carboxycroman-4-one.](image)

Although Teixeira [6] isolated a similar substance from fruits of *P. gaudichaudianum*, this is the first time that 2,2-dimethyl-6-carboxycroman-4-one has been isolated from the leaves of this species. The benzoic acid isomers were previously isolated from leaves of *Piper murrayanum* [17], and leaves
of *Piper lhotzkyanum* [18]. Recently, 4-hydroxy-(3',7'-dimethyl-1'-oxo-octa-2'-6'-dienyl) benzoic acid was isolated and identified in a dichloromethane-methanol fraction obtained from the roots of *Piper crassinervium* [16]. Many benzoic acid derivatives have been isolated from species of Piperaceae and identified. This is the first report of this isomer in *P. gaudichaudianum*.

A previous report by Silva and co-workers [17] showed that the hydroalcoholic extract and the amides piperovatine and piperlonguminine from *P. ovatum* Vahl have good antimicrobial activity against *B. subtilis* and *C. tropicalis*. Another study reported the antibacterial activity of both crude extract and purified active compound of *Piper regnellii*, traditionally used in Brazilian folk medicine to treat infectious diseases [18] The compound that showed antibacterial activity against methicillin-resistant *S. aureus* (MRSA) was identified as eupomatenoid-5 by spectroscopic analysis.

In a 2010 study by Koroishi et al., the *in vitro* antidermatophyte activity of the extracts and derivatives from leaves of *Piper regnellii* showed great antifungal activity against *Trichophyton rubrum*, and nail lacquer containing its chloroform fraction may have great potential to treat onychomycosis caused by these microorganisms [19].

The crude extract and the fractions were tested against *S. aureus*, by bioautography (Figure 3). We observed a zone of inhibition in fraction F2 (dichloromethane-ethyl acetate, 95:5). The crude extract and other fractions showed no inhibition zones. The MICs of the aqueous extract, crude extract, fractions, and pure compounds tested against strains of *S. aureus*, *E. coli*, *Pseudomonas aeruginosa*, *B. subtilis*, *Candida albicans*, *C. parapsilosis*, *C. tropicalis*, and *T. rubrum* by broth microdilution are presented in Tables 1 and 2.

**Figure 3.** Bioautographic crude extracts and fractions isolated from the leaves of *P. gaudichaudianum*. The plate A was used for bioautography with *S. aureus* and the plate B was revealed with reactive Godin. Arrows indicate zones of inhibition of the fraction F2 and the band corresponding to the chromatographic plate. The reference compound on the plate was amikacin (C).
Table 1. Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and minimum fungicidal concentration (MFC) of aqueous and crude extracts obtained from the leaves of *P. gaudichaudianum* and antibiotics used.

| Samples/Antibiotics | Antimicrobial Activity (µg/mL) | S. aureus | B. subtilis | E. coli | P. aeruginosa | C. albicans | C. tropicalis | C. parapsilosis | T. rubrum |
|---------------------|-------------------------------|-----------|-------------|---------|---------------|--------------|---------------|----------------|----------|
|                     | MIC MBC                        | MIC MBC   | MIC MBC    | MIC MBC | MIC MBC       | MIC MFC      | MIC MFC       | MIC MFC        |          |
| AE                  | >1000 -                        | >1000 -   | >1000 -    | >1000 - | >1000 -       | >1000 -      | >1000 -       | >1000 -        | >1000 - |
| CE                  | 250 500 250 500 62,5 62,5 62,5 | 1000      | 62,5 125   | 62,5 125| 62,5 125      | 1000 -       | 62,5 125      | 1000 -         | 1000 -   |
| Ceftriaxone         | 6,25 -                         | -         | -          | -       | -             | -            | -             | -              |          |
| Chloraphenicol      | 12,5 -                         | -         | -          | -       | -             | -            | -             | -              |          |
| Penicillin          | 0,02 -                         | -         | -          | -       | -             | -            | -             | -              |          |
| Tetracycline        | 0,39 -                         | -         | -          | -       | -             | -            | -             | -              |          |
| Vancomycin          | 1,25 -                         | 0,2 -     | -          | -       | -             | -            | -             | -              |          |
| Fluconazole         | -                              | -         | -          | -       | -             | -            | -             | 7,8 >250 -     | 1,9 1,56 |

Table 2. Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and minimum fungicidal concentration (MFC) of fractions and pure compounds obtained from the leaves of *P. gaudichaudianum*.

| Samples/Antibiotics | Antimicrobial Activity (µg/mL) | S. aureus | B. subtilis | E. coli | P. aeruginosa | C. albicans | C. tropicalis | C. parapsilosis | T. rubrum |
|---------------------|-------------------------------|-----------|-------------|---------|---------------|--------------|---------------|----------------|----------|
|                     | MIC MBC                        | MIC MBC   | MIC MBC    | MIC MBC | MIC MBC       | MIC MFC      | MIC MFC       | MIC MFC        |          |
| F1                  | 1000 -                         | 1000 -    | >1000 -    | >1000 - | >1000 -       | 62,5 125    | >1000 -       | >1000 -        | 500 -    |
| F2                  | 62,5 62,5                      | 15,6 15,6 | >1000 -    | >1000 - | >1000 -       | 62,5 125    | >1000 -       | >1000 -        | 250 -    |
| F3                  | 125 >1000                      | 31,2 31,2 | >1000 -    | >1000 - | >1000 -       | 250 500     | >1000 -       | >1000 -        | 500 -    |
| F4                  | >1000 -                        | >1000 -   | >1000 -    | >1000 - | >1000 -       | 500 500     | >1000 -       | >1000 -        | 1000 -   |
| F5                  | >1000 -                        | >1000 -   | >1000 -    | >1000 - | >1000 -       | 1000 >1000  | >1000 -       | >1000 -        | 1000 -   |
| FDA 47-58           | 31,25 62,5                     | 7,81 7,81 | >1000 -    | >1000 - | >1000 -       | 1000 -      | >1000 -       | >1000 -        |          |
| FDB 9               | 12,5 12,5                      | 6,25 6,25 | >1000 -    | >1000 - | >1000 -       | >1000 -     | >1000 -       | >1000 -        |          |

(-) unspecified.
The crude extract showed good activity against *B. subtilis* and *C. tropicalis* with MIC of 62.5 μg/mL, moderate activity against *S. aureus* with MIC of 250 μg/mL, weak activity against *T. rubrum* with MIC of 1,000 μg/mL, and had no effect on the other microorganisms. The aqueous extract proved to be inactive against the microorganisms tested. Fraction F1 (hexane) showed good activity against *C. tropicalis* with MIC of 62.5 μg/mL, moderate activity against *T. rubrum* with MIC of 500 μg/mL and was inactive against the other microorganisms.

Fraction F2 (dichloromethane-ethyl acetate 95:5) showed good activity against *B. subtilis*, *S. aureus*, and *C. tropicalis* with MICs of 15.6 μg/mL, 62.5 μg/mL, and 62.5 μg/mL, respectively; moderate activity against *T. rubrum* with MIC of 250 μg/mL; and was inactive against the other microorganisms.

Fraction F3 (dichloromethane-ethyl acetate 50:50) showed good activity against *B. subtilis* with MIC of 31.2 μg/mL, moderate activity against *S. aureus*, *C. tropicalis*, and *T. rubrum* with MIC 125 μg/mL, 250 μg/mL, and 500 μg/mL respectively; and was inactive against the other microorganisms.

Fraction F4 (ethyl acetate) showed moderate activity against *C. tropicalis* with MIC 500 μg/mL, and was inactive against the others. Fraction F5 (methanol) was inactive against all microorganisms tested.

Purified substances FDA 47-58 and FDB 9 showed activity against the bacteria *S. aureus* and *B. subtilis*, with MIC of 31.25 μg/mL and 12.5 μg/mL for *S. aureus*, respectively, and 7.81 μg/mL and 6.25 μg/mL for *B. subtilis* respectively.

Although the bioautography test showed an inhibition zone only against *S. aureus* for the F2 fraction, the minimum inhibitory concentration test showed that the EB, fraction F3 and F1, also possessed activity against *S. aureus* (Tables 1 and 2). The low MICs could explain the absence of the inhibition of the other fractions and EB in the assays.

In general, secondary metabolites of plants are a source of bioactive substances, and scientific interest in these has been increasing during the search for new drugs, as well as new centers that can serve as model compounds. Chromones are not as abundant in *Piper* species as are amides, lignoids, phenylpropanoids and terpenes, but these substances are rich in pharmacological potential. Chromones in immature and mature fruits of *P. gaudichaudianum* show activity against *E. faecium*, *M. luteus*, and *S. faecium* [6]. Salazar et al. [16] found antifungal activity of chromones of leaves and stems of *Peperomia villipetiola* against Cladosporium cladosporioides and *C. sphaerospermum*. Chromones isolated from *Peperomia serpens* also showed antifungal activity [20]. Other chromones obtained through synthesis have shown activity against MRSA [21]. Chromones and chromanones isolated from a methanol extract of *Hypericum sikokumontanum* showed activity against *Helicobacter pylori* in a study by Tanaka et al. [22]. *Piper hostmannianum* and *Piper aduncum* yielded a benzoic-acid derivative 3-(2-hydroxy-3-methyl-3-butenyl)-4-methylhydroxybenzoate with molluscicidal activity [23,24]. From *Piper lanceaefolium*, prenylated derivatives of benzoic acid that had antifungal activity were isolated [25]. *Piper multiplinervium* accumulates a derivative of benzoic acid with antimicrobial activity against *S. aureus*, *E. coli*, *Klebsiella pneumoniae*, *Mycobacterium smegmatis*, *P. aeruginosa*, and *C. albicans* [26]. These studies indicate a tendency for chromones and derivatives of benzoic acid to show antimicrobial activity, as also found in this study (Table 2).

The synergism of the crude extract, fraction F2, and ejection fraction F3 with antibiotics of different classes was verified through the checkerboard technique and the isobologram (Figure 4). The MIC of ceftriaxone was 6.25 μg/mL when the drug was tested alone, and decreased to 1.56 μg/mL in the
presence of 100 μg/mL of fraction F3. For vancomycin, MIC was 1.25 μg/mL when tested alone, and decreased to 0.31 μg/mL in the presence of 50 μg/mL of fraction F2.

Figure 4. (A) Isobologram representing synergy between ceftriaxone and F3 against *S. aureus*; (B) Isobologram representing synergism between vancomycin and F2 against *S. aureus*; (C) Isobologram representing synergism between tetracycline and F3 against *S. aureus*; The dashed line indicates the theoretical additive activity.
For tetracycline, the MIC was 0.39 μg/mL when tested alone, and decreased to 0.09 μg/mL in the presence of 100 g/mL of fraction F3. Several studies of natural products have demonstrated the effect of the combination of drugs against microorganisms. Stermitz et al. [13] demonstrated the synergistic activity of porphyrin compounds and flavonolignans with the alkaloid berberine; the compounds inhibited the efflux pump of *S. aureus*, potentiating the antibacterial effect of berberine. Compounds such as diterpenes isolated from *Rosmarinus officinalis* and *Lycopus europaeus* showed a synergistic effect with erythromycin against resistant strains of *S. aureus* [27-30].

3. Experimental

3.1. General

The NMR spectra were obtained in a Bruker ARX400 (9.4 T) and Varian Gemini 300 (7.05 T) instruments, using deuterated solvent for field homogeneity, TMS as internal standard and temperature constant of 298 K. IR: film NaCl plates; ES-MS were recorded on a Micro-mass Quattro LC, HRMS: Auto-spec Micro-mass EBE and EI-MS on a CG/EM-SHIMADZU QP 2,000 A. CC: silica gel 60 (70–230 and 230–400 mesh); TCL: silica gel plates F254 (0.25 mm in thickness).

3.2. Plant Material

Leaves of *P. gaudichaudianum* were collected in August of 2008 in the Didactic Garden and Experimental Biology Department of the campus of the State University of Maringá. A voucher specimen (HUM 9616) was deposited in the herbarium of the Department of Botany of the State University of Maringá, Paraná.

3.3. Plant Extraction and Purification

The leaves (720 g) of the *P. gaudichaudianum* were extracted with ethanol-water (9:1 v/v, 7L) for 48 h at room temperature. The solvent was removed under vacuum at 40 °C to give an aqueous extract and a dark green residue. The aqueous extract from the crude hydroalcoholic extract was lyophilized (16.4 g) and the residue from crude extract in glass bottle was washed with dichloromethane. The organic solvent was removed to give the dichloromethane extract (11.87 g), which was chromatographed in a vacuum silica-gel apparatus, eluted with gradients of hexane, dichloromethane-ethyl acetate (95:5 v/v), dichloromethane-ethyl acetate (1:1 v/v), ethyl acetate and methanol, affording fractions F1 (0.44 g), F2 (2.72 g), F3 (1.18 g), F4 (0.7 g) and F5 (4.62 g). The dichloromethane-ethyl acetate (1:1 v/v) fraction F3 was rechromatographed on a silica gel 60 (70–230 mesh) column eluted with gradients of the hexane, hexane/EtOAc (95:5, 90:10, 80:20, 70:30, 60:40 and 50:50 v/v), EtOAc, EtOAc/MethOH (95:5, 75:25 and 50:50) and MeOH, affording 191 fractions. The combined subfractions 47–58 (29.70 mg) were identified as a chromone (2,2-dimethyl-6-carboxycroman-4-one). The dichloromethane-ethyl acetate (95:5 v/v) fraction F2 was rechromatographed on a silica gel 60 (70–230 mesh) column eluted with gradients of the hexane, hexane/EtOAc (80:20, 70:30, 60:40 and 50:50 v/v), EtOAc, and MeOH, affording 156 fractions. The subfractions 9 (17.50 mg) was identified as isomeric prenylated benzoic acid derivatives [4-hydroxy-(3',7'-dimethyl-1'-oxo-octa-2'-6'-dienyl) benzoic acid and 4-hydroxy-(3',7'-dimethyl-1'-oxo-octa-2'-Z-6'-dienyl) benzoic acid]. The chemical structures of
the isolated substances were determined by \textsuperscript{1}H-NMR, R\textsuperscript{13}C-NMR, COZY, DEPT, HMQC, HMBC spectral analysis of and by comparison with values reported in the literature \cite{6,16}.

2,2-Dimethyl-6-carboxycroman-4-one. The chemical structure was determined in comparison with values of NMR spectra in the literature \cite{6}, DEPT, HMQC, HMBC and by comparison with other literature data \cite{6,16}. \textsuperscript{1}H-NMR (CDCl\textsubscript{3}, 300 MHz): \(\delta 2.8 (\text{d}, J = 16.5 \text{ Hz}, \text{H-3a}); 2.71 (\text{d}, J = 16.5 \text{ Hz}, \text{H-3b}); 8.63 (\text{d}, J = 2.1 \text{ Hz}, \text{H-5}); 8.18 (\text{dd}, J = 8.7 \text{ Hz and } J = 2.1 \text{ Hz}, \text{H-7}); 7.01 (\text{d}, J = 8.7 \text{ Hz}, \text{H-8}); 1.58 (\text{s}, \text{H1''}); 1.58 (\text{s}, \text{H2''}). \textsuperscript{13}C-NMR (CDCl\textsubscript{3}, 75.50 MHz): \(\delta 82.54 (\text{C-2}); 47.38 (\text{C-3}); 191.77 (\text{C-4}); 130.07 (\text{C-5}); 120.10 (\text{C-6}); 137.49 (\text{C-7}); 118.97 (\text{C-8}); 163.87 (\text{C-9}); 122.29 (\text{C-10}); 167.91 (\text{C-1'}); 25.88 (\text{C-1'' and 2''}).

4-Hydroxy-(3',7'-dimethyl-1'-oxo-octa-2'-E-6'-dienyl) benzoic acid. The chemical structure was determined in comparison with the NMR spectra values in the literature \cite{16}. \textsuperscript{1}H-NMR (CDCl\textsubscript{3}, 300 MHz): \(\delta 7.03 (\text{d}, J = 9 \text{ Hz}, \text{H-3}); 8.15 (\text{dd}, J = 1.5 \text{ and } 9 \text{ Hz}, \text{H-4}); 8.56 (\text{d}, J = 1.8 \text{ Hz}, \text{H-6}); 6.84 (\text{s}, \text{H-8}); 2.29–2.35 (\text{m}, \text{H-10}); 2.33–2.37 (\text{m}, \text{H-11}); 5.15–5.18 (\text{m}, \text{H-12}); 1.65 (\text{s}, \text{H-14}); 1.67 (\text{s}, \text{H-15}); 2.22 (\text{s}, \text{H-16}); 13.42 (\text{s}, \text{OH}). \textsuperscript{13}C-NMR (CDCl\textsubscript{3}, 75.50 MHz): \(\delta 119.86 (\text{C-1}); 167.94 (\text{C-2}); 119.39 (\text{C-3}); 137.32 (\text{C-4}); 120.38 (\text{C-5}); 133.28 (\text{C-6}); 196.05 (\text{C-7}); 119.12 (\text{C-8}); 163.7 (\text{C-9}); 41.89 (\text{C-10}); 26.12 (\text{C-11}); 122.81 (\text{C-12}); 130.08 (\text{C-13}); 25.90 (\text{C-14}); 16.48 (\text{C-15}); 20.50 (\text{C-16}); 170.62 (\text{COOH}).

4-Hydroxy-(3',7'-dimethyl-1'-oxo-octa-2'-Z-6'-dienyl) benzoic acid. \textsuperscript{1}H-NMR (CDCl\textsubscript{3}, 300 MHz): \(\delta 7.03 (\text{d}, J = 9 \text{ Hz}, \text{H-3}); 8.15 (\text{dd}, J = 1.5 \text{ and } 9 \text{ Hz}, \text{H-4}); 8.56 (\text{d}, J = 1.8 \text{ Hz}, \text{H-6}); 6.84 (\text{s}, \text{H-8}); 2.01–2.1 (\text{m}, \text{H-10}); 2.29–2.31 (\text{m}, \text{H-11}); 5.15–5.18 (\text{m}, \text{H-12}); 1.65 (\text{s}, \text{H-14}); 1.64 (\text{s}, \text{H-15}); 2.24 (\text{s}, \text{H-16}); 13.42 (\text{s}, \text{OH}). \textsuperscript{13}C-NMR (CDCl\textsubscript{3}, 75.50 MHz): \(\delta 119.86 (\text{C-1}); 167.94 (\text{C-2}); 119.39 (\text{C-3}); 137.32 (\text{C-4}); 120.38 (\text{C-5}); 133.28 (\text{C-6}); 196.05 (\text{C-7}); 119.12 (\text{C-8}); 163.7 (\text{C-9}); 35.75 (\text{C-10}); 26.12 (\text{C-11}); 122.81 (\text{C-12}); 130.08 (\text{C-13}); 25.90 (\text{C-14}); 16.48 (\text{C-15}); 26.13 (\text{C-16}); 170.62 (\text{COOH}).

3.4. Thin Layer Chromatography

Kieselgel GF\textsubscript{254} plates, 20 \times 20 \text{ cm}, 1 \text{ mm thick}, were used. Plant extracts (1 \mu g/mL) were applied (50 \mu L) and the chromatogram developed using hexane-ethyl acetate (50:50) as solvent. TLC plates were run in duplicate and one set was used as the reference chromatogram. Spots and bands were visualized by UV irradiation (245 and 366 nm) and Godin’s Reactive (solution of 1\% of vanillin and perchloric acid in a 1:1 proportion). The other set was used for bioautography. Amikacin (12.8 \mu g, Bristol Myers Squibb) was used as reference antibiotic.

3.5. Strains and Growth Conditions

The test microorganisms used included \textit{Staphylococcus aureus} ATCC 25923, \textit{Escherichia coli} ATCC 25922, \textit{Pseudomonas aeruginosa} ATCC 27853 and \textit{Bacillus subtilis} ATCC 6623, \textit{Candida albicans} ATCC 10231, \textit{Candida parapsilosis} ATCC 22019, \textit{C. tropicalis} ATCC 28707, \textit{Trichophyton rubrum} rubrum ATCC 28189.

Bacteria were maintained on Mueller Hinton Agar and sub cultured in Mueller Hinton Broth before each experiment. Yeasts were maintained at 4 \textdegree C on Sabouraud Dextrose Agar plates and sub cultured
at 37 °C in Sabouraud Dextrose Broth before each experiment, to ensure viability and purity. The dermatophyte, was maintained on Sabouraud Dextrose Agar slants at 10 °C and sub cultured monthly throughout this study.

3.6. Bioautography

Chromatograms developed as described above were placed in a square plate with cover and inoculums of *S. aureus* containing 10⁶ CFU/mL in molten Mueller-Hinton agar was distributed over the place. After solidification of the medium, the TLC plate was incubated overnight at 37 °C. Subsequently the bioautogram was sprayed with an aqueous solution of 2,3,5-triphenyltetrazolium chloride (TTC) and incubated at 37 °C for 4 h. Inhibition zones indicated the presence of active compounds.

3.7. Antibacterial Susceptibility Testing

The minimum inhibitory concentrations (MICs) of all compounds and reference antibiotics were determined by micro dilution techniques in Mueller Hinton broth for bacteria, and Sabouraud broth for yeasts, described by the Clinical and Laboratory Standards Institute (CLSI) [34]. Inoculates were prepared in the same medium at a density adjusted to a 0.5 McFarland turbidity standard (10⁶ colony-forming units [CFU]/mL) and diluted 1:10 for the broth micro dilution procedure. Micro titer trays were incubated at 37 °C, and the MICs were recorded after 24 h for bacteria and 48 h for yeast of incubation. For dermatophyte the period of incubation time was 72 h at 28 °C. Two susceptibility endpoints were recorded for each isolate. The MIC was defined as the lowest concentration of compounds at which the microorganism tested did not demonstrate visible growth. Minimum bactericidal concentration (MBC) and Minimum fungicidal concentration (MFC) were defined as the lowest concentration yielding negative subcultures or only one colony.

3.8. Scanning Electron Microscopy

To investigate the effect of fraction F2 and vancomycin alone and in combination on the morphology of *S. aureus*, treated and control cells were examined by scanning electron microscopy. Cells were fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.2, and small drops of the fixed cells were placed on a specimen support with poly-L-lysine for 1 h at room temperature. Subsequently, the samples were dehydrated in a graded ethanol series, critical-point dried in CO₂, coated with gold, and examined under a Shimadzu SS-550 scanning electron microscope (Figure 5).

3.9. Checkerboard

From the results of the minimum inhibitory concentration tests, the combination of EB, F2, and F3 was done with the antibiotic ceftriaxone, chloramphenicol, penicillin, tetracycline, and vancomycin using the “checkerboard” method against the bacterium *S. aureus*. The combinations of EB and fractions with the antibiotics were tested in Mueller-Hinton Broth with an inoculum of 1 × 10⁴ CFU/mL of *S. aureus* and different concentrations of the drug, ranging from 500 to 3.13 µg/mL, and antibiotics, ranging from 25 to 0.01 µg/mL.
Figure 5. Scanning electron microscopy. (A) *S. aureus* without treatment (control); (B) *S. aureus* treated with fraction F2 (50 μg/mL); (C and D) *S. aureus* treated with vancomycin (0.63 μg/mL). (E and F) *S. aureus* treated with combinations of fraction F2 (6.25 μg/mL) and vancomycin (0.63 μg/mL).

In a 96-well plate, each well received 100 μL of HCM, except column 12A, which received 200 μL of the antibiotic to be tested. The remaining wells of column 12 received 100 μL of each antibiotic, followed by serial dilutions to column 2. Then, the wells of the line received 100 μL of EB or fractions, followed by serial dilutions up to row G. Row H and column 1 were the controls for the antibiotic and EB/fractions, respectively. Each well contained a combination of different concentrations of EB and fractions with antibiotics. The plates were incubated at 37 °C for 24 h, and the results were assessed by observing the inhibition of visible growth [35,36]. The combinations of the substances were analyzed by calculating the FIC index (FICI) as follows: FIC = (MICa of the combination/MICa alone) + (MICb of the combination/MICb alone). The FIC was interpreted as: (i) a
synergistic effect when ≤0.5; (ii) an additive or indifferent effect when >0.5 and ≤4; and (iii) an antagonistic effect when >4 [37]. The combination of the two components is shown graphically by a Cartesian diagram, by applying the isobole method. The non-interaction of the two components results in a straight line, whereas the occurrence of an interaction is shown by a concave isobole [38].

4. Conclusions

The results of this study of the antimicrobial properties of fractions and mainly of pure substances, together with their synergistic activity, is promising from the standpoint of medicinal chemistry, in the search for bioactive compounds from plants that may provide prototype molecules for the synthesis of more potent, selective, less-toxic and low-cost analogues. However we need to carry out further research to elucidate the mechanism of action of synergistic components, as well as their applications as viable antimicrobial agents.

Acknowledgements

This study was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Capacitação e Aperfeiçoamento de Pessoal de Nível Superior, (Capes), Fundação Araucária, and Programa de Pós-graduação em Ciências Farmacêuticas da Universidade Estadual de Maringá. Part of the experiments were carried out at the Complexo de Central de Apoio a Pesquisa (COMCAP) MCT/FINEP/UEM.

References and Notes

1. Rates, S.M.K. Plants as source of drugs. Toxicon 2001, 39, 603-613.
2. Montanari, C.A.; Bolzani, V.S. Planejamento racional de fármacos baseados em produtos naturais. Química Nova 2001, 24, 105-111.
3. Souza, V.C.; Lorenzi, H. Botânica e Sistemática: Guia ilustrado para identificação das famílias de fanerógamas nativas e exóticas no Brasil, baseado em APG II, 2nd ed.; Nova Odessa, Instituto Plantarum: São Paulo, Brazil, 2008; p. 640.
4. Parmar, V.S.; Jain, S.C.; Bisht, K.S.; Jain, R.; Taneja, P.; Jha, A.; Tyagi, O.D.; Prasad, A.K.; Wengel, J.; Olsen, C.E.; Boll, P.M. Phytochemistry of the genus Piper. Phytochemistry 1997, 46, 597-673.
5. Facundo, V.A.; Silveira, A.S.P.; Morais, S.M. Constituents of Piper alatabaccum Trel & Yuncker (Piperaceae). Biochem. Systemat. Ecol. 2005, 33, 753-756.
6. Teixeira, S.D. Phytochemical study of Piper gaudichaudianum and its interaction with Frugívoros bats. PhD Thesis. Federal University of Parana, Curitiba, Brazil, 2003; p. 164.
7. Batista Junior, J.M.; Lopes, A.A.; Regasini, L.O.; Ambrósio, D.L.; Cicarelli, R.M.; Bolzani, V.S.; Kato, M.J.; Furlan, M. Potential anti-chagasic chromenes natural and synthetic analogs semmi-Piper aduncum and Piper gaudichaudianum (Piperaceae), Brazilian Chemical Society (SBQ), 28º Annual Meeting of the Brazilian Society of Chemistry, São Paulo, Brazil, 2005.
8. Trabulsi, L.R.; Alterthum, F. Microbiology, 4th ed.; Editora Atheneu: São Paulo, Brazil, 2004; p. 718.
9. Martineu, F.; Picard, F.J.; Ke, D.; Paradis, S.; Hoy, P.H. Development of a PCR assay for identification of *Staphylococci* at genus and species levels. *J. Clin. Microbiol.* **2001**, *39*, 2541-2547.

10. Jones, R.N.; Hare, R.S.; Sabatelli, F.J. *In vitro* gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobial: A multicentre international trial. *J. Antimicrob. Chemother.* **2001**, *47*, 15-25.

11. Harbart, S. Controlo f endemic methicillin-resistant *Staphylococcus aureus*—Recent advances and future challenges. *Clin. Microbiol. Infect.* **2006**, *12*, 1154-1162.

12. Santos, A.L.; Santos, D.O.; Freitas, C.C.; Ferreira, B.L.A.; Afonso, I.F.; Rodrigues, C.R.; Castro, H.C. *Staphylococcus aureus*: Visiting a hospital strain of importance. *J. Bras. Patol. Med. Lab.* **2007**, *43*, 413-423.

13. Stermitz, F.; Lorenz, P.; Tawara, J.N.; Zenewicz, L.A.; Lewis, K. Synergy in a medicinal plant: Antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 1433-1437.

14. Khan, I.A.; Mirza, Z.M.; Kumar, A.; Verma, V.; Qazi, G.N. Piperine, a phytochemical potentiator of ciprofloxacin against *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **2006**, *50*, 810-812.

15. Smith, E.C.J.; Kaatz, G.W.; Seo, S.M.; Wareham, N.; Williamson, E.M.; Gibbons, S. The phenolic diterpene totarol inhibit multidrug efflux pump activity in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **2007**, *51*, 4480-4483.

16. Silva, R.F. Secondary metabolites of the roots of *Piper crassinervium* Kunth (Piperaceae). Master Thesis. Chemistry Institute, University of São Paulo, São Paulo, Brazil, 2006, p. 92.

17. Silva, D.R.; Endo, E.H.; Dias Filho, B.P.; Nakamura, C.V.; Svidzinski, T.I.E.; Souza, A.; Young M.C.M.; Ueda-Nakamura, T.; Cortez, D.A.G. Chemical composition and antimicrobial properties of *Piperovatum* Vahl. *Molecules* **2010**, *15*, 2060-2069.

18. Marçal, F.J.B.; Cortez, D.A.G.; Ueda-Nakamura, T.; Nakamura, C.V.; Dias Filho, B.P. Activity of the Extracts and Neolignans from *Piper regnellii* against Methicillin-Resistant *Staphylococcus aureus* (MRSA). *Molecules* **2010**, *15*, 3920-3931.

19. Dias Filho, B.P. Antifungal activity and nail permeation of nail lacquer containing *Piper regnellii* (Miq.) C. CD. var. *pallescens* (C. DC.) Yunck (Piperaceae) leave extracts and derivatives. *Molecules* **2010**, *15*, 3920-3931.

20. Seeram, N.P.; Jacobs, H.; McIeran, S.; Reynolds, W.F. Prenylated hydroxybenzoic acid derivatives from *Piper murrayanum*. *Phytochemistry* **1996**, *43*, 863-865.

21. Moreira, D.; Guimarães, E.F.; Kaplan, M.A.C. Non-polar constituents from leaves of *Piper lhotzkyanum*. *Phytochemistry* **1998**, *49*, 1339-1342.

22. Salazar, K.J.M.; Paredes, G.E.D.; Lluncor, L.R.; Young, M.C.M.; Kato, M.J. Chromones of polyketide origin from *Peperonia villipetiola*. *Phytochemistry* **2005**, *66*, 573-579.

23. Kitmura, R.O.S.; Romoff, P.; Young, M.C.M.; Kato, M.J.; Lago, J.H.G. Chromones from *Peperomia serpens* (Sw.) Loudon (Piperaceae). *Phytochemistry* **2006**, *67*, 2398-2402.

24. Diwakar, D.S.; Bhagwat, S.S.; Shingare, M.S.; Gill, C.H. Substituted 3-((Z)-2-(4-nitrophenyl)-2-(1H-tetrazol-5-yl) vinyl)-4H-chromen-4-ones as novel anti-MRSA agents: Synthesis, SAR, and *in-vitro* assessment. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 4678-4681.
25. Tanaka, N.; Kashiwada, Y.; Nakano, T.; Shibata, H.; Higuchi, T.; Sekiya, M.; Ikeshiro, Y.; Ikeshiro, Y. Chromone and chromanone glucosides from Hypericum sikokumontanum and their anti-Helicobacter pylori activities. *Phytochemistry* **2009**, *70*, 141-146.

26. Diaz, P.P.; Ariais, T.; Joseph-nathan, P. A. chromene, a isoprenylated methyl hydroxybenzoate and a C-methylflavone from the bark *Piper hostmannianum*. *Phytochemistry* **1987**, *26*, 809-811.

27. Orjala, J.; Edelmeier, C.A.J.; Wright, A.D.; Rali, T.; Sticher, O. Two chromenes and a prenylated benzoic acid derivative from *Piper aduncum*. *Phytochemistry* **1993**, *34*, 813-818.

28. López, A.; Ming, D.S.; Towers, G.H.N. Antifungal activity of benzoic acid derivatives from *Piper lanceaefolium*. *J. Nat. Prod.* **2002**, *65*, 62-64.

29. Rüegg, T.; Calderón, A.I.; Queiroz, E.F.; Solis, P.N.; Marston, A.; Rivas, F.; Ortega-Barria, E.; Hostettmann, K.; Gupta, M.P. 3-Farnesyl-2-hydroxybenzoic acid is a new anti-Helicobacter pylori compound from *Piper multiplinervium*. *J. Ethnopharmacol.* **2006**, *103*, 461-467.

30. Gibbons, S.; Oluwatuyi, M.; Veitch, N.C.; Gray, A.I. Bacterial resistance modifying agents from Lycopus europaeus. *Phytochemistry* **2003**, *62*, 83-87.

31. Rosato, A.; Vitali, C.; Laurentis, N. Antibacterial effect of some essential oils administered alone or in combination with norfloxacin. *Phytomedicine* **2007**, *14*, 727-732.

32. Scott, E.M.; Tariq, V.N.; McCrory, R.M. Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. *Antimicrob. Agents Chemother*. **1995**, *12*, 2610-2614.

33. Marchetti, O.; Moreillon, P.; Glauser, M.P.; Bille, J.; Sanglard, D. Potent synergism of the combination of fluconazole and cyclosporine in *Candida albicans*. *Antimicrob. Agents Chemother*. **2000**, *44*, 2373-2381.

34. Odds, F.C. Synergy, antagonism, and what the checkerboard puts between them. *J. Antimicrob. Chemother*. **2003**, *52*, 1.

35. Williamsom, E.M. Synergy and other interactions in phytomedicines. *Phytomedicine* **2001**, *8*, 401-409.

Sample Availability: Samples of the compounds are available from the authors.

© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).